Analysis Shows Credo’s VitaPCR™ SARS-CoV-2 Related Assays Covers New Virus Strain
Credo Diagnostics Biomedical Pte. Ltd., the leader of point-of-care rapid molecular diagnostic, announced today it has completed internal analysis and confirmed that all its VitaPCR™ SARS-CoV-2 related assays – including the VitaPCR™ SARS-CoV-2 Assay, the VitaPCR™ SARS-CoV-2 Gen 2 Assay, and the Influenza A&B/SARS-CoV-2 Assay – can successfully detect the newly discovered variant strain of […]
VitaPCR™ Influenza A&B/SARS-CoV-2 assay Receives CE Mark
Credo Diagnostics Biomedical Pte. Ltd., the leader of point-of-care rapid molecular diagnostic, announced today it has received CE-Mark for the VitaPCR™ Influenza A&B/SARS-CoV-2 assay, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, and Flu B infections from a single patient sample. The three-in-one test is designed for use […]
Credo Diagnostics Biomedical VitaPCR™ SARS-CoV-2 Assay Garners CE Mark
Credo Diagnostics Biomedical Pte. Ltd. announced today that it has obtained the CE Mark for its SARS-CoV-2 Assay. The rapid point-of-care molecular test for the novel Coronavirus COVID-19 is now commercially available in markets recognizing the designation. Leveraging its real-time PCR point-of-care platform VitaPCR™, the test allows the detection of SARS-CoV-2 in 20 minutes with […]
Credo Diagnostics Biomedical is finalizing a rapid point-of-care molecular test for the detection of novel Coronavirus COVID-19 in 20 minutes
To date, the novel Coronavirus has killed more than 2,000 people with more than 75,000 confirmed cases worldwide. Leveraging its real-time PCR point-of-care platform, the VitaPCRTM, which was introduced during the American Association of Clinical Chemistry Conference (AACC) in Anaheim last year, the test will deliver results in 20 minutes with a hands-on time of […]
Join us at the MEDLAB for a Demo
Credo Diagnostics Biomedical Pte. Ltd., a groundbreaking point-of-care rapid molecular diagnostic company, announced today they will attend the Medlab Middle East exhibition that will take place at the Dubai World Trade Centre from February 3 to February 6. Credo Diagnostics Biomedical will be showcasing it product line of point-of-care molecular diagnostic solution including the VitaPCR™ […]
VitaPCR™ to be Featured on CNBC
Credo Diagnostics Biomedical Pte. Ltd., a groundbreaking point-of-care rapid molecular diagnostic company, will be featured in the newest episode of Advancements with Ted Danson that will broadcast Nationwide via CNBC on Saturday, September 21st @11:00am ET. The segment will focus on Credo Diagnostics Biomedical’s new molecular diagnostic platform, VitaPCR. Combining speed, accuracy, and ease-of-use required […]
VitaPCR™ to be Launched at the AACC Clinical Expo
Credo Diagnostics Biomedical Pte. Ltd., a groundbreaking point-of-care rapid molecular diagnostic company, announced today they will introduce their new molecular diagnostic platform, VitaPCR™, and its Influenza A/B assay, at the 71st AACC Clinical Expo that will take place in Anaheim on 6th, 7th, and 8th August 2019. Based on real-time polymerase chain reaction (real-time PCR), […]
Join us at the WVC Conference for a Demo
Singapore, February 15, 2019 – Credo Diagnostics Biomedical Pte. Ltd., a groundbreaking molecular diagnostic company, announced today they will attend the 91st WVC Conference that will take place in Las Vegas February 17th to 20th. Credo Diagnostics will be introducing doing live demo of of CUBE PCR, its revolutionary point-of-care molecular diagnostic solution, for the […]
